CEL-SCI's 15min chart triggered Bullish Marubozu, Bearish Marubozu signal.

CEL-SCI's 15-minute chart recently exhibited a Bullish Marubozu and a Bearish Marubozu at 09/23/2025 11:00. This indicates that buyers dominated the market during the specified timeframe, suggesting a continuation of bullish momentum. Conversely, the Bearish Marubozu signifies that sellers controlled the market during the same period, implying a potential continuation of bearish momentum.

Several small-cap stocks extended their momentum into after-hours trading on Thursday, posting sharp gains following active regular sessions. The rally appears to be driven by renewed investor interest, strategic updates, leadership moves, and pipeline developments. Here are some notable gains:

1. Adaptimmune Therapeutics plc (ADAP) surged 30% in after-hours trading, jumping to $0.2020 from its regular session close of $0.16. This dramatic overnight move followed a nearly 98% gain during Thursday's trading session, where the stock closed at $0.16 after opening at just $0.08. The volume also spiked, with over 705 million shares traded, well above its average daily volume of 60 million. While no company-specific news was released on September 19, recent strategic updates, including the sale of TECELRA to US WorldMeds for $55 million upfront, may have driven the renewed attention After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].

2. Butterfly Network Inc. (BFLY) extended its rally into after-hours trading, climbing 10.58% to $2.09 following a strong regular session performance where the stock closed at $1.89, up 15.95% from the previous close. The surge comes amid heightened investor interest and volume, with over 12 million shares traded, triple its average daily volume. Recent recognition and strategic developments, such as being named to TIME's list of the World's Top HealthTech Companies for 2025 and appointing a new Chief Technology Officer, may have contributed to the momentum After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].

3. Aquestive Therapeutics Inc. (AQST) continued its upward momentum in after-hours trading, rising 7.69% to $5.32 following a solid regular session gain of 2.28%, where it closed at $4.94. The stock has been steadily climbing, now up nearly 39% year-to-date, and trading near the upper end of its 52-week range of $2.12 to $5.80. The FDA's decision not to require an advisory committee meeting for its NDA for Anaphylm, streamlining the regulatory path, may have bolstered investor sentiment After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].

4. ALX Oncology Holdings Inc. (ALXO) extended its gains in after-hours trading, rising 9.17% to $1.19 following a 3.81% increase during Thursday's regular session, where it closed at $1.09. The latest catalyst appears to be insider buying activity, with CEO Jason Lettmann purchasing 92,233 shares of ALXO on September 17. While no new clinical data were released this week, the company's lead candidate, Evorpacept, remains in multiple Phase 1 and Phase 2 trials across various cancer types After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].

5. Ekso Bionics Holdings Inc. (EKSO) continued its upward momentum in after-hours trading, rising 5.37% to $4.51 after closing Thursday's regular session at $4.28, a gain of 9.74%. Recent developments, such as its inclusion in the NVIDIA Connect Program and the launch of Virtual eksoUniversity, may be contributing to the stock's strength After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].

6. CEL-SCI Corp. (CVM) rose 5.27% in after-hours trading on Thursday, reaching $9.39 after closing the regular session at $8.92, up 1.02% for the day. While there were no new announcements on September 19, recent developments, including a $10 million public offering and the filing for Breakthrough Medicine Designation in Saudi Arabia for its lead candidate, Multikine, may be shaping the company's outlook After-Hours Trading Sees Sharp Gains Across Emerging Growth Names^[1].